These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 8540056)

  • 1. Cytomegalovirus prophylaxis in antibody-treated renal transplanted patients.
    Birkeland S; Gahrn-Hansen B; Andersen H; Rohr N; Larsen KE; Jørgensen A
    Transplant Proc; 1995 Dec; 27(6):3473-6. PubMed ID: 8540056
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
    So S; Mayo C; McCullough C; Jendrisak M; Woodle S; Marsh W; Bailey T
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865
    [No Abstract]   [Full Text] [Related]  

  • 3. Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study.
    Legendre C; Ducloux D; Ferroni A; Chkoff N; Valette C; Geffrier C; Rouzioux C; Kreis H
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1431-3. PubMed ID: 8382871
    [No Abstract]   [Full Text] [Related]  

  • 4. Ganciclovir treatment for cytomegalovirus infections in renal transplant recipients.
    Buturović-Ponikvar J; Kandus A; Malovrh M; Ponikvar R; Kveder R
    Transplant Proc; 1992 Oct; 24(5):1921-3. PubMed ID: 1329287
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of immunosuppressive therapy on infectious complications in renal transplant recipients.
    Klauser R; Zlabinger GJ; Traindl O; Franz M; Watschinger B; Pohanka E; Kudlacek S; Kovarik J
    Transplant Proc; 1992 Feb; 24(1):292-4. PubMed ID: 1539284
    [No Abstract]   [Full Text] [Related]  

  • 6. Preemptive therapy with gancyclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation.
    van Son WJ; van den Berg AP; The TH; Tegzess AM
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1436-8. PubMed ID: 8382873
    [No Abstract]   [Full Text] [Related]  

  • 7. Minimizing the toxicity of antilymphocyte antibody therapy.
    Pascual M; Rubin RH; Cosimi AB
    Transplant Proc; 1996 Aug; 28(4):2113-4. PubMed ID: 8769171
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K; Munn SR; Sterioff S
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract]   [Full Text] [Related]  

  • 9. Incidence of de novo malignancies in renal transplant patients after anti-T-lymphocytic therapy.
    Kosch M; Könecke J; Hausberg M; Kisters K
    Clin Nephrol; 2001 Dec; 56(6):S35-6. PubMed ID: 11770811
    [No Abstract]   [Full Text] [Related]  

  • 10. Prophylaxis for cytomegalovirus in pancreas transplant recipients using intravenous ganciclovir.
    Kohli V; Velosa J; Sterioff S; Munn SR
    Transplant Proc; 1995 Dec; 27(6):2993. PubMed ID: 8539806
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
    Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
    Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination of cytomegalovirus disease in liver transplant patients treated prophylactically with combination cytomegalovirus hyperimmune globulin and ganciclovir.
    Prian GW; Koep LJ
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):54-5. PubMed ID: 7940977
    [No Abstract]   [Full Text] [Related]  

  • 13. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
    Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S
    Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OKT3 monoclonal antibody therapy and visual loss.
    Horina JH; Horn S; Holzer H; Langmann G
    Nephrol Dial Transplant; 1996 Jul; 11(7):1497-8. PubMed ID: 8815436
    [No Abstract]   [Full Text] [Related]  

  • 15. Cytomegalovirus infection during OKT3 treatment for renal allograft rejection.
    Morgan JD; Horsburgh T; Simpson A; Donnelly PK; Veitch PS; Bell PR
    Transplant Proc; 1992 Dec; 24(6):2634-5. PubMed ID: 1334589
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of steroid resistant acute rejection after renal transplantation.
    Oh CK; Kim YS; Kim MS; Kim SI; Park K
    Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737
    [No Abstract]   [Full Text] [Related]  

  • 18. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection.
    Dickenmann MJ; Kabulbayev K; Steiger J; Cathomas G; Reusser P; Tamm M
    Clin Microbiol Infect; 2004 Apr; 10(4):337-9. PubMed ID: 15059125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis of viral infections under therapy with OKT3 and antithymocyte globulin.
    Müller T; Sprenger H; Keuchel M; Neumann C; Ebel H; Gemsa D; Lange H
    Transplant Proc; 1992 Dec; 24(6):2636-8. PubMed ID: 1334590
    [No Abstract]   [Full Text] [Related]  

  • 20. Measures to improve early results in kidney transplantation.
    Schweizer RT; Roper L; Hull D; Bartus S
    Transplant Proc; 1992 Dec; 24(6):2729-30. PubMed ID: 1465919
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.